A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo.

@article{Kondou2003ABP,
  title={A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo.},
  author={Hiroki Kondou and Sotaro Mushiake and Yuri Etani and Yoko Miyoshi and Toshimi Michigami and Keiichi Ozono},
  journal={Journal of hepatology},
  year={2003},
  volume={39 5},
  pages={742-8}
}
BACKGROUND/AIMS Thrombospondin-1 is a major activator of transforming growth factor-beta1 (TGF-beta1), and a peptide derived from the latency-associated peptide, Leu-Ser-Lys-Leu (LSKL), inhibits the activation of TGF-beta1. In this study, the effects of LSKL on the hepatocyte damage and fibrogenesis in dimethylnitrosamine (DMN)-induced rat liver fibrosis were examined. METHODS Animals were given an intraperitoneal (i.p.) injection of DMN or saline three times per week for 4 weeks, and treated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Active immunization against transforming growth factor beta1 prevents hepatic fibrosis in a rat model of liver disease.

Canadian journal of physiology and pharmacology • 2017
View 5 Excerpts
Highly Influenced

The Roles of Thrombospondins in Hemorrhagic Stroke

BioMed research international • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…